Comparison of Religious Cognitive Behavioral Therapy, Cognitive Behavioral Therapy, and Citalopram on Depression and Anxiety among Women with Breast Cancer: A Study Protocol for a Randomized Controlled Trial

Seyed Hamzeh Hosseini, Alireza Rafiei Ghasem Janbabai, Abdolhakim Tirgari Aliasghar Zakavi, Jamshid Yazdani, Jafar Bolhari, Manhood Golzari,Nazanin Vaezzadeh,Zahra


There has been evidence supporting the reduction of depression and anxiety by religious psychotherapy in cancer patients,
however, there have been scarce randomized controlled trials. Therefore, there is a need for replication in a well-designed
study to investigate the efficacy of these interventions among depressed women with breast cancer. A randomized
controlled trial is designed to be conducted on 160 women with breast cancer. Participants will be screened for anxiety
and depression diagnosed by clinical interview based on the DSM-IV criteria and the Hospital Anxiety Depression Scale.
Golriz and Baraheni’s Religious Attitude Questionnaire will be used to assess the religious attitude. Individuals meeting
the prerequisites will be randomly allocated to four groups, each containing 40 participants, including three intervention
groups (RCBT, CBT, and citalopram) and one control group (usual breast cancer treatment). An instrument by the
EORTCQLQ-C30 and BR-23 will be used to measure the quality of life. Blood tests will be taken to assess biomarkers with
the (ELISA) method. The results will determine whether RCBT is more effective than other treatments. If so, the outcomes
of the study will have implications not only for the management of similar problems in cancer patients but also for the
management of other chronic diseases.


Anxiety, Biomarker, Breast Cancer, Citalopram, Cognitive Behavioral Therapy, Depression, Quality of Life, Religious Cognitive Behavioral Therapy

Full Text:



Malvezzi M, Arfe A, Bertuccio P, Levi F, la Vecchia C, Negri

E. European cancer mortality predictions for the year 2011.

Annals of Oncology. 2011; 22(4):947–56.

Allemani C, Weir HK, Carreira H, Harewood R, Spika D,

Wang XS, et al. Global surveillance of cancer survival 1995-

: analysis of individual data for 25676887 patients from

population-based registries in 67 countries (CONCORD-

. Lancet. 2014 Nov 26.

O’Connor M, Christensen S, Jensen AB, Moller S, Zachariae

R. How traumatic is breast cancer? Post-traumatic stress

symptoms (PTSS) and risk factors for severe PTSS at 3 and

months after surgery in a nationwide cohort of Danish

women treated for primary breast cancer. Br J Cancer. 2011

Feb 1; 104(3):419–26.

Galloway SK, Baker M, Giglio P, Chin S, Madan A, Malcolm

R, et al. Depression and anxiety symptoms relate to distinct

components of pain experience among patients with breast

cancer. Pain Research and Treatment.2012; 2012:851276.

Olin JJ. Cognitive function after systemic therapy for breast

cancer. Oncology (Williston Park, NY). 2001; 15(5):613–8.

Meyers CA. How chemotherapy damages the central nervous

system. J Biol. 2008; 7(4):11.

Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa

E, Sugawara Y, et al. Association between adjuvant regional

radiotherapy and cognitive function in breast cancer

patients treated with conservation therapy. Cancer Med.

Jun; 3(3):702–9.

Montazeri A. Health-related quality of life in breast cancer

patients: a bibliographic review of the literature from 1974

to 2007. Journal of Experimental andClinical Cancer Research.

; 27(1):32.

Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner

R. Effects of psycho-oncologic interventions on emotional

distress and quality of life in adult patients with cancer:

systematic review and meta-analysis.J Clin Oncol. 2013;


Blume J, Douglas SD, Evans DL. Immune suppression and

immune activation in depression. Brain, Behavior, and Immunity.

; 25(2):221–9.

Raison CL, Miller AH. Depression in cancer: new developments

regarding diagnosis and treatment. Biological Psychiatry.

; 54(3):283–94.

Raison CL, Capuron L, Miller AH. Cytokines sing the blues:

inflammation and the pathogenesis of depression. Trends

Immunol. 2006 Jan; 27(1):24–31.

Osborne L, Gispen F, Meilman S, Gocke A, Tosi D, Payne J.

Increased inflammatory markers in late pregnancy depression:

the role of progesterone and allopregnanolone. Brain,

Behavior, and Immunity. 2015; 49:22-3.

Roque S, Correia-Neves M, Mesquita AR, Palha JA, Sousa

N. Interleukin-10: a key cytokine in depression? Cardiovasc

Psychiatry Neurol. 2009; 2009:187894.

Gazal M, Jansen K, Souza LD, Oses JP, Magalhães PV, Pinheiro

R, et al. Association of interleukin-10 levels with age

of onset and duration of illness in patients with major depressive

disorder. Revista Brasileira de Psiquiatria. 2015;


Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L,

Reim EK, et al. A meta-analysis of cytokines in major depression.

Biol Psychiatry. 2010 Mar 1; 67(5):446–57.

Tavakoli-Ardakani M, Mehrpooya M, Mehdizadeh M, Hajifathali

A, Abdolahi A. Association between Interlukin-6

(IL-6), Interlukin-10 (IL-10) and depression in patients

undergoing hematopoietic stem cell transplantation. International

Journal of Hematology-Oncology and Stem Cell

Research. 2015; 9(2):80.

Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa

A, McGuire H, et al. Escitalopram versus other antidepressive

agents for depression. Cochrane Database Syst Rev.


Shiroma PR, Thuras P, Johns B, Lim KO. Emotion recognition

processing as early predictor of response to 8-week

citalopram treatment in late-life depression. Int J Geriatr

Psychiatry. 2014 Apr 4.

Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg

CL, Lunetta KL, et al. Tamoxifen’s protection against

breast cancer recurrence is not reduced by concurrent use of

the SSRI citalopram. Br J Cancer. 2008 Aug 19; 99(4):616–21.

Vol 8(S1) | 2016 | Asian Journal of Pharmaceutical Research and Health Care

Comparison of Religious Cognitive Behavioral Therapy, Cognitive Behavioral Therapy, and Citalopram on Depression and

Anxiety among Women with Breast Cancer: A Study Protocol for a Randomized Controlled Trial

Rizzo M, Creed F, Goldberg D, Meader N, Pilling S. A systematic

review of non-pharmacological treatments for depression

in people with chronic physical health problems. J

Psychosom Res. 2011 Jul; 71(1):18–27.

Garlick M, Wall K, Corwin D, Koopman C. Psycho-spiritual

integrative therapy for women with primary breast

cancer. J Clin Psychol Med Settings. 2011 Mar;18(1):78–90.

Fallah R, Golzari M, Dastani M, Akbari ME. Integrating

spirituality into a group psychotherapy

program for women surviving from breast cancer. Iranian

Journal of Cancer Prevention. 2011; 4(3):141–3.

Olver IN, Dutney A. A randomized, blinded study of the

impact of intercessory prayer on spiritual well-being in patients

with cancer. Altern Ther Health Med. 2012 Sep-Oct;


Shaw B, Han JY, Kim E, Gustafson D, Hawkins R, Cleary J,

et al. Effects of prayer and religious expression within computer

support groups on women with breast cancer. Psycho-

Oncology. 2007; 16(7):676–87.

Koenig HG. Religious versus conventional psychotherapy

for major depression in patients with chronic medical illness:

rationale, methods, and preliminary results. Depress

Res Treat. 2012; 2012:460419.

Andrews JG, Oei TPS. The roles of depression and anxiety

in the understanding and treatment of obstructive

sleep apnea syndrome. Clinical Psychology Review. 2004;


McGregora BA, Antonib MH. Psychological intervention

and health outcomes among women treated for breast cancer:

a review of stress pathways and biological mediators.

Brain, Behavior, and Immunity. 2009; 23(2):159–66.

Jafari N, Zamani A, Farajzadegan Z, Bahrami F, Emami H,

Loghmani A. The effect of spiritual therapy for improving

the quality of life of women with breast cancer: a randomized

controlled trial. Psychology, Health andMedicine.


Paiva CE, Paiva BS, deCastro RA, Souza CP, de Paiva Maia

YC, Ayres JA, et al. A pilot study addressing the impact of

religious practice on quality of life of breast cancer patients

during chemotherapy. J Relig Health. 2013 Mar; 52(1):184–

Ursaru M, Crumpei I, Crumpei G. Quality of life and religious

coping in women with breast cancer. Procedia - Social

and Behavioral Sciences. 2014 Feb21; 114:322–6.

Pearce M, Koenig HG. Cognitive behavioural therapy for

the treatment of depression in Christian patients with medical

illness. Mental Health, Religion and Culture. 2013;


Koenig HG. Religious versus conventional psychotherapy

for major depression in patients with chronic medical illness:

rationale, methods, and preliminary results. Depression

Research and Treatment. 2012;2012.

Pearce MJ, Koenig HG, Robins CJ, Nelson B, Shaw SF, Cohen

HJ, et al. Religiously integrated cognitive behavioral

therapy: A new method of treatment for major depression

in patients with chronic medical illness. Psychotherapy.

; 52(1):56.

Bayanzadeh S, Bolhary J, Dadfar M, Karimi Keisomi I. Effectiveness

of cognitive-behavioral religious-cultural therapy

in improvement of obsessive-compulsive patients. Razi

Journal of Medical Sciences. 2005; 11(44):913–23.

Bellinger D, Berk L, Koenig HG, Daher D, Pearce M, Robins

C, et al. Religious involvement, inflammatory markers

and stress hormones in major depression and chronic medical

illness.Open Journal of Psychiatry. 2014; 4(4):335–52.

Walpole SC, McMillan D, House A, Cottrell D, Mir G. Interventions

for treating depression in Muslim patients: a systematic

review. J Affect Disord. 2013 Feb 15; 145(1):11–20.

Lim C, Sim K, Renjan V, Sam HF, Quah SL. Adapted cognitive-

behavioral therapy for religious individuals with mental

disorder: a systematic review. Asian J Psychiatr. 2014

Jun; 9:3–12.

Sharifi V, Asadi SM, Mohammadi MR, Homayoun KHA,

Semnani Y, Shabanikia A, et al. Reliability and feasibility of

the Persian version of the structured diagnostic interview

for DSM-IV (SCID). Advances in Cognitive Science. 2004.

Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The

hospital anxiety and depression scale (HADS): translation

and validation study of the Iranian version. Health and

Quality of Life Outcomes. 2003; 1(1):14.

Koenig H. Cognitive behavioral treatments for depression

in patients with chronic illness. Available from: wwwspiritualityand

health dukeedu//Full%20Protocol. 2014.

Sadeghi M, Ladari RB, Haghshenas M. A study of religious

attitude and mental health in students of Mazandaran University

of Medical Sciences. Journal of Mazandaran University

of Medical Sciences. 2010; 20(75):70–5.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull

A, Duez NJ, et al. The European organization for research

and treatment of cancer QLQ-C30: a quality-of-life instrument

for use in international clinical trials in oncology.

Journal of the National Cancer Institute. 1993; 85(5):365–

Hamid N, Behslideh K, Bayghi MA, Dehghanizadeh Z.

A study of the effect of religion-based cognitive-behavior

therapy on depression in divorced women. Journal of Family

Counseling andPsychotherapy. 2011; 1(1):54–64.

Kontodimopoulos N, Ntinoulis K, Niakas D. Validity of the

Greek EORTC QLQ-C30 and QLQ-BR23 for measuring

health-related quality of life in breast cancer patients. Eur J

Cancer Care (Engl). 2011 May; 20(3):354–61.

Montazeri A, Harirchi I, Vahdani M, Khaleghi F, Jarvandi S,

Ebrahimi M, et al. The EORTC breast cancer-specific quality

of life questionnaire (EORTC QLQ-BR23): translation

and validation study of the Iranian version. Quality of Life

Research. 2000; 9(2):177–84.

Sadeghi M, Ladari RB, Haghshenas M. A study of religious

attitude and mental health in students of Mazandaran university

of medical sciences. Journal of Mazandaran University

of Medical Sciences. 2010; 20:(75):70–5.

Beck J. Cognitive behavior therapy: basics and beyond. 2nd

ed. New York: Guilford Press; 2011.


  • There are currently no refbacks.


 Creative Commons 

Listed as Green Publisher